Such MyD88 competent cancer cells are theoretically able to exploit current chemotherapeutic strategies, by not only resisting their cytotoxic effects but also by using paclitaxel-ligation to facilitate their growth and that of the surrounding stroma via enhanced NF-κB production. This evidence concerns the gene MYD88 and cancer.